Press Releases

01/18/2024

Product Launch

Tempus Introduces xM MRD to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

Data on xM presented at the 2024 ASCO® Gastrointestinal Cancers Symposium Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM MRD (formerly xM), to its comprehensive testing solutions. The tumor-naïve plasma based test is available for research use only to detect circulating tumor DNA (ctDNA) in th...

01/05/2024

Tempus to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Tempus, a leader in artificial intelligence and precision medicine, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 8-11, 2024. Tempus Founder and CEO, Eric Lefkofsky, will deliver a presentation and host a Q&A with the investment community at the conference on M...

01/02/2024

Tempus Announces Participation in National Cancer Institute’s ComboMATCH Trials

Tempus, a leader in artificial intelligence and precision medicine, today announced its participation in the National Cancer Institute’s (NCI) ComboMATCH group of precision medicine trials. The ComboMATCH trials aim to pair patients with a therapy that has the potential to manage their tumor and help assist physicians in devisi...

11/28/2023

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Exclusive arrangement will expand market access to Personalis’ ultra-sensitive MRD test Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL) and Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal® Dx, Personalis’ whole genome-based liqui...

11/20/2023

Tempus Welcomes City of Hope Comprehensive Cancer Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that City of Hope Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers represents over 30 medical centers that are leveraging the program to advance...

11/15/2023

Tempus Announces Medicare Coverage for Tempus xT Across Solid Tumor and Hematologic Malignancies

Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’ CAP/CLIA laborator...

11/09/2023

Tempus Announces New Strategic Collaboration with Recursion to Advance Therapeutic Development

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with Recursion (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working together to advance biomarker-driven therapeutic development with a data-first approach. Through this coll...

11/08/2023

Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease mode...

11/07/2023

Tempus Welcomes Rush University Medical Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that Rush University Medical Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research...

11/03/2023

Tempus Announces New ctDNA Assay, xM Monitor

Tumor uninformed treatment response monitoring assay for research use only Tempus, a leader in artificial intelligence and precision medicine, today announced xM Monitor (formerly xF Monitor) – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy fo...

NEWS

Media Coverage

Additional Partnerships